[1]董 冰,郭阳丹,范 晶,等.埃克替尼联合胸腔镜肺叶切除术治疗EGFR敏感突变的晚期非小细胞肺癌临床价值研究[J].陕西医学杂志,2026,(5):659-663.[doi:DOI:10.3969/j.issn.1000-7377.2026.05.015]
　DONG Bing,GUO Yangdan,FAN Jing,et al.Clinical value of icotinib combined with thoracoscopic lobectomy in the treatment of advanced non-small cell lung cancer with EGFR-sensitive mutations[J].,2026,(5):659-663.[doi:DOI:10.3969/j.issn.1000-7377.2026.05.015]
点击复制

埃克替尼联合胸腔镜肺叶切除术治疗EGFR敏感突变的晚期非小细胞肺癌临床价值研究

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2026年5期
页码:
659-663
栏目:
药物与临床
出版日期:
2026-05-05

文章信息/Info

Title:
Clinical value of icotinib combined with thoracoscopic lobectomy in the treatment of advanced non-small cell lung cancer with EGFR-sensitive mutations
作者:
董 冰; 郭阳丹; 范 晶; 张国燕; 张建辉
（山西医科大学附属运城市中心医院胸外科，山西 运城 044000）
Author(s):
DONG Bing; GUO Yangdan; FAN Jing; ZHANG Guoyan; ZHANG Jianhui
(Department of Thoracic Surgery,Yuncheng Central Hospital Affiliated to Shanxi Medical University,Yuncheng 044000,China）
关键词:
晚期非小细胞肺癌; 埃克替尼; 胸腔镜肺叶切除术; 表皮生长因子受体; 正五聚蛋白3; 缺氧诱导因子-1α; 免疫功能; 肺功能
Keywords:
Advanced non-small cell lung cancer; Icotinib; Thoracoscopic lobectomy; Epidermal growth factor receptor; Pentraxin 3; Hypoxia-inducible factor-1α; Immune function; Pulmonary function
分类号:
R734.2
DOI:
DOI:10.3969/j.issn.1000-7377.2026.05.015
文献标志码:
A
摘要:
目的：探讨埃克替尼联合胸腔镜肺叶切除术对表皮生长因子受体(EGFR)敏感突变的晚期非小细胞肺癌（NSCLC）患者的治疗效果，并观察其对血清正五聚蛋白3（PTX3）、缺氧诱导因子-1α（HIF-1α）水平以及免疫功能和肺功能的影响。方法：选取102例EGFR敏感突变、临床分期为Ⅳ期且具备手术适应证的NSCLC患者，随机分为对照组和观察组，各51例。对照组行胸腔镜肺叶切除术，观察组在相同手术基础上联合埃克替尼治疗。比较两组疗效，检测治疗前后血清PTX3、HIF-1α水平、免疫功能及肺功能指标变化，并统计治疗期间不良反应。结果：观察组疾病控制率（DCR）高于对照组（P<0.05）。治疗前，两组CD4+、CD8+百分比及CD4+/CD8+比值、血清PTX3、HIF-1α水平、肺功能指标比较差异无统计学意义（均P＞0.05）。治疗后，两组CD4+百分比、CD4+/CD8+比值、最大通气量（MVV）、第一秒用力呼气容积占预计值百分比（FEV1%）、用力肺活量占预计值百分比（FVC%）较治疗前升高，CD8+百分比、血清PTX3、HIF-1α水平较治疗前降低，且观察组以上指标改善程度优于对照组（均P<0.05）。两组不良反应发生率比较差异有统计学意义（P＜0.05）。结论：埃克替尼联合胸腔镜肺叶切除术治疗EGFR敏感突变的晚期NSCLC可有效提升疾病控制率，改善免疫功能与肺功能，降低血清PTX3和HIF-1α水平，并且安全性良好。
Abstract:
Objective:To investigate the therapeutic efficacy of icotinib combined with thoracoscopic lobectomy in patients with advanced NSCLC harboring epidermal growth factor receptor (EGFR)-sensitive mutations,and to observe its effects on serum pentraxin 3 (PTX3),hypoxia-inducible factor-1α (HIF-1α) levels,immune function and pulmonary function.Methods：A total of 102 patients with EGFR-sensitive mutations,clinical stage Ⅳ NSCLC,and surgical indications were enrolled and randomly divided into the control group (51 cases) and the observation group (51 cases).The control group underwent thoracoscopic lobectomy alone,while the observation group received icotinib combined with the same surgical procedure.The therapeutic efficacy was compared between the two groups.Before and after treatment,Serum PTX3 and HIF-1α levels,immune function,and pulmonary function indicators were detected.Adverse reactions were also recorded.Results:The disease control rate (DCR) in the observation group was higher than that in the control group (P<0.05).Before treatment,no statistically significant differences were observed in CD4+ and CD8+ percentages,CD4+/CD8+ ratio,serum PTX3 and HIF-1α levels,or pulmonary function indicators between the two groups (all P>0.05).After treatment,CD4+ percentage,CD4+/CD8+ ratio,maximum voluntary ventilation (MVV),forced expiratory volume in the first second as a percentage of predicted value (FEV1%) and forced vital capacity as a percentage of predicted value (FVC%) increased in both groups,while CD8+ percentage and serum PTX3 and HIF-1α levels decreased compared with baseline.The improvement in these indicators was more pronounced in the observation group than in the control group (all P<0.05).There was statistically significant difference in the incidence of adverse reactions between the two groups (P<0.05).Conclusion:Icotinib combined with thoracoscopic lobectomy for advanced NSCLC with EGFR-sensitive mutations can effectively improve disease control rate,enhance immune and pulmonary function,reduce serum PTX3 and HIF-1α levels,and demonstrate favorable safety.

参考文献/References:

[1]中华医学会肿瘤学分会.中华医学会肺癌临床诊疗指南（2023版）[J].中华肿瘤杂志,2023,45(4):220-268.
[2]SIEGEL R L,MILLER K D,FUCHS H E,et al.Cancer statistics,2023[J].CA Cancer J Clin,2023,73(1):17-48.
[3]王洁.晚期非小细胞肺癌精准治疗的现状与未来[J].中华肿瘤杂志,2024,46(2):101-106.
[4]吴一龙,周彩存,程颖,等.埃克替尼治疗晚期表皮生长因子受体突变非小细胞肺癌的Ⅳ期临床研究[J].中华肿瘤杂志,2022,44(8):821-827.
[5]石远凯.埃克替尼治疗非小细胞肺癌中国专家共识(2021年版)[J].中国新药杂志,2021,30(9):803-808.
[6]赵珩,陈海泉.胸腔镜手术在晚期非小细胞肺癌姑息治疗中的应用价值[J].中华胸心血管外科杂志,2024,40(3):136-140.
[7]李雪纯,姜舒,陈铮,等.基于生物数据挖掘分析PTX3在非小细胞肺癌中的表达及其与预后的关系[J].现代生物医学进展,2022,22(4):707-712.
[8]BASHEERUDDIN M,QAUSAIN S.Hypoxia-inducible factor 1-alpha (HIF-1α) and cancer:Mechanisms of tumor hypoxia and therapeutic targeting[J].Cureus,2024,16(10):e70700.
[9]中国临床肿瘤学会.非小细胞肺癌诊疗指南（2023版）[M].北京:人民卫生出版社,2023:35-45.
[10]周彩存.晚期非小细胞肺癌治疗的现状与挑战[J].中国肺癌杂志,2024,27(1):1-8.
[11]董利.盐酸埃克替尼片靶向治疗对非小细胞肺癌患者血清肿瘤标志物水平的影响[J].中国实用医刊,2024,51(5):91-94.
[12]陈建华,徐文浩,石翔.甲磺酸奥希替尼对比埃克替尼治疗非小细胞肺癌的临床效果分析[J].中外医疗,2024,43(9):89-92.
[13]王国伟,何苡,侯广杰,等.肺癌患者单孔胸腔镜下肺叶切除术后心肺并发症的危险因素研究[J].海南医学,2025,36(2):191-195.
[14]李敏,王媛,李震,等.血清HIF-1α、PD-L1、VEGF-C、VEGFR-3水平对非小细胞肺癌患者淋巴结转移的预测价值[J].实用癌症杂志,2025,40(2):218-222,226.
[15]刘畅,陈明,张颖.EGFR-TKI联合手术治疗非小细胞肺癌的分子机制及临床应用进展[J].中华肿瘤防治杂志,2024,31(7):532-537.
[16]许娟娟,王希文,卢江.埃克替尼联合全胸腔镜肺叶切除术对老年晚期非小细胞肺癌患者血清PTX3及CCL20水平的影响[J].解放军预防医学杂志,2018,36(12):1578-1580.
[17]杨震,赵志杰,冯宗妹,等.葫芦巴碱调节HIF-1α/VEGF信号通路对非小细胞肺癌增殖、迁移和侵袭能力的影响[J].现代生物医学进展,2024,24(18):3429-3436.
[18]安术祥,周斌,王家富.全胸腔镜下行肺叶切除术治疗早期非小细胞肺癌的疗效分析[J].系统医学,2024,9(9):124-126,130.
[19]张敏,刘杰,赵刚.非小细胞肺癌患者血清HIF-1α、PTX3及CEA水平联合检测的临床意义[J].临床肺科杂志,2023,28(8):1195-1199.
[20]危靖怡,宁辉,董佳琪,等.蔓荆子黄素通过HIF-1α调控糖代谢抑制非小细胞肺癌细胞的增殖[J].中国中药杂志,2024,49(24):6755-6762.
[21]瞿介明,吕凡,宋元林.非小细胞肺癌的缺氧微环境与靶向治疗策略[J].中华结核和呼吸杂志,2024,47(5):481-486.
[22]侯士于,樊涛,徐瑞凤.安罗替尼联合盐酸埃克替尼治疗晚期非小细胞肺癌合并脑转移的疗效与安全性分析[J].临床研究,2025,33(2):34-37.
[23]贺垒,陈小霞.非小细胞肺癌患者全胸腔镜肺叶切除术远期预后及危险因素分析[J].临床研究,2024,32(8):48-50.
[24]刘立红,孟庆军,任明明,等.单孔胸腔镜肺叶切除术治疗高龄NSCLC患者的近期疗效研究[J].保健医学研究与实践,2024,21(10):25-30.
[25]王实慧,汤姝.埃克替尼联合吉西他滨、顺铂化疗对晚期非小细胞肺癌患者血管新生和治疗获益的影响[J].中国医院药学杂志,2024,44(11):1317-1321.

备注/Memo

备注/Memo:
国家自然科学基金资助项目（81971655）
更新日期/Last Update: 2026-05-05